Abstract 178P
Background
Lenvatinib (LEN) has demonstrated the efficacy and safety in patients (pts) with advanced HCC (aHCC) as first-line treatment in the pivotal REFLECT trial. Further evaluation in real-world setting is necessary to measure the clinical outcomes of LEN in daily practice.
Methods
This is a multicenter retrospective analysis from 3 Korean referral cancer institutions. Between September 2018 and November 2019, a total of 86 pts received LEN for the management of BCLC B or C aHCC, and 75 pts who had at least one follow-up visit after the start of LEN were included in this analysis.
Results
Median age was 59 years (range, 19-81), and 56 pts (74.7%) were male. Baseline characteristics were as follows; Child-Pugh class A/B in 57 (76.0%)/18 (24.0%), BCLC B/C in 9 (12.0%)/66 (88.0%), prior systemic therapy in 24 (32.0%) including 14 (18.7%) with prior immune checkpoint inhibitors (ICIs). LEN was used as 1st/2nd/3rd-4th lines of therapy in 51 (68.0%)/13 (17.3%)/11 (14.7%) pts, and 30 (40.0%) had extensive disease extent excluded in the REFLECT trial. In overall pts, the median follow-up duration was 4.7 months (mo) (95% CI, 3.3-6.2), the median PFS and OS were 4.6 (95% CI, 3.6-5.6) and 6.7 mo (95% CI, 5.0-8.3), repectively. In Child-Pugh A group, the PFS and OS were as follows: 1st line setting, 4.6 (95% CI,3.1-6.1) and 10.7 mo (95% CI, 4.7-16.6); >= 2nd line setting, 4.4 (95% CI, 2.8-6.0) and 6.4 mo (95% CI,4.7-8.0); prior ICI group 4.4 (95% CI, 3.6-5.1) and 7.1 mo (95% CI, 5.7-8.5), respectively. In Child-Pugh B group, the PFS and OS were 2.6 (95% CI, 0.6-4.6) and 5.3 mo (95% CI, 2.0-8.5), respectively. According to the RECIST v 1.1, response rates and disease control rate were 10.7% and 77.4%, respectively, in overall pts. The most common grade 3-4 toxicities were hyperbilirubinemia (n=8, 10.7%), AST elevation (n=6, 8.0%) and diarrhea (n=4, 5.3%).
Conclusions
LEN was effective and well tolerated in pts with aHCC in Korean real-life setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
C. Yoo: Advisory/Consultancy: Bayer; Advisory/Consultancy: Eisai; Advisory/Consultancy: Ipsen; Advisory/Consultancy: MSD. All other authors have declared no conflicts of interest.
Resources from the same session
24P - The Pink Vans: Bringing cancer screening closer to home
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
25P - Identification of gene mutations in patients with breast cancer in a region located in the southeast of the European part of Russia
Presenter: Alexander Sultanbaev
Session: e-Poster Display Session
26P - Body mass index and clinical outcomes in Egyptian women with breast cancer: A multi-institutional study
Presenter: Amrou Mamdouh Abdeen Shaaban
Session: e-Poster Display Session
27P - Breast cancer primary site and laterality as predictive factors of prognosis: SEER based analysis for survival
Presenter: Eman Zin Eldin
Session: e-Poster Display Session
28P - Breast cancer care services at Nilai Medical Centre: A Malaysian experience
Presenter: Ratnavelu Kananathan
Session: e-Poster Display Session
29P - Factors affecting breast self-examination (BSE) behaviour among female high school students in Denpasar City, Bali
Presenter: Cindy Trisina
Session: e-Poster Display Session
30P - Male breast cancer: A rural based peripheral cancer center experience
Presenter: SACHIN KHANDELWAL
Session: e-Poster Display Session
31P - The prognostic value of pre-treatment peripheral neutrophil-lymphocyte-ratio (NLR) and its correlation with mutant p53 expression in Indonesian triple negative breast cancer patients
Presenter: Rosita Purwanto
Session: e-Poster Display Session
32P - Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience
Presenter: Izzet Dogan
Session: e-Poster Display Session
33P - FDG-PET predictivity of pathological axillary nodal status in carcinoma breast-upfront and post-neoadjuvant chemotherapy (NACT) setting
Presenter: Krithikaa Sekar
Session: e-Poster Display Session